ood morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because the time has come to dive into the fast-growing to-do list of meetings, deadlines, and the like. You knew this would happen, yes? We find the best way to cope is to grab a cup of stimulation — our choice today is pecan pie — or a bottle of water, if you prefer. So time to get cracking. Hope you have a smashing day and do stay in touch …

A Japanese health ministry panel approved the withdrawal of a fast-track designation for Merck’s (MRK) Keytruda as a gastric cancer treatment after the rival Opdivo sold by Bristol-Myers Squibb (BMY) was granted the indication, Pharma Japan tells us. Keytruda was awarded fast-track status in 2015, but after Opdivo was approved last month, the Merck drug no longer meets the novelty threshold, which is one of four eligibility criteria for fast-track designation.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Pharmaceutical production
Drug Pricing

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.